MX2019001084A - Variantes de gpr156 y usos de estas. - Google Patents

Variantes de gpr156 y usos de estas.

Info

Publication number
MX2019001084A
MX2019001084A MX2019001084A MX2019001084A MX2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A
Authority
MX
Mexico
Prior art keywords
gpr156
aspartic acid
disclosure
protein
alterations
Prior art date
Application number
MX2019001084A
Other languages
English (en)
Spanish (es)
Inventor
Gonzaga-Jauregui Claudia
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019001084A publication Critical patent/MX2019001084A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
MX2019001084A 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas. MX2019001084A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (1)

Publication Number Publication Date
MX2019001084A true MX2019001084A (es) 2019-06-10

Family

ID=59649989

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001084A MX2019001084A (es) 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas.
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Country Status (13)

Country Link
US (4) US10266582B2 (https=)
EP (2) EP4230648A3 (https=)
JP (2) JP7556688B2 (https=)
KR (2) KR20240027874A (https=)
CN (1) CN109563516B (https=)
AU (1) AU2017302611B2 (https=)
CA (1) CA3032124A1 (https=)
DK (1) DK3491014T5 (https=)
IL (1) IL264473A (https=)
MX (2) MX2019001084A (https=)
NZ (1) NZ751010A (https=)
SG (1) SG11201900738YA (https=)
WO (1) WO2018022967A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7556688B2 (ja) * 2016-07-28 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Gpr156変異体及びその使用
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN113423266A (zh) * 2019-01-17 2021-09-21 雷杰纳荣制药公司 情绪障碍的啮齿动物模型

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
JPH10510700A (ja) 1993-06-04 1998-10-20 アメリカ合衆国 アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
AU6343400A (en) * 1999-07-09 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2001079230A2 (en) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
JP2007535538A (ja) * 2004-04-29 2007-12-06 メルク エンド カムパニー インコーポレーテッド アゼチジングリシン輸送体インヒビター
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
AU2013262709A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
MX2018007674A (es) * 2015-12-21 2018-09-12 Bayer Oy Un metodo para la fabricacion de un anillo vaginal.
JP7556688B2 (ja) * 2016-07-28 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Gpr156変異体及びその使用

Also Published As

Publication number Publication date
JP2019527229A (ja) 2019-09-26
KR20190034532A (ko) 2019-04-02
EP4230648A3 (en) 2023-10-18
EP4230648A2 (en) 2023-08-23
CN109563516A (zh) 2019-04-02
DK3491014T3 (da) 2023-05-30
US10266582B2 (en) 2019-04-23
CN109563516B (zh) 2023-10-27
KR102661616B1 (ko) 2024-04-30
EP3491014A1 (en) 2019-06-05
US20220073589A1 (en) 2022-03-10
AU2017302611A1 (en) 2019-03-14
JP2023071704A (ja) 2023-05-23
DK3491014T5 (da) 2024-09-02
KR20240027874A (ko) 2024-03-04
US20180030114A1 (en) 2018-02-01
EP3491014B1 (en) 2023-04-05
US10562953B2 (en) 2020-02-18
NZ751010A (en) 2024-11-29
WO2018022967A1 (en) 2018-02-01
AU2017302611B2 (en) 2021-12-09
CA3032124A1 (en) 2018-02-01
US20200231651A1 (en) 2020-07-23
JP7556688B2 (ja) 2024-09-26
MX2024013403A (es) 2024-12-06
US20190202891A1 (en) 2019-07-04
SG11201900738YA (en) 2019-02-27
IL264473A (en) 2019-02-28
US11155598B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
MX2024013403A (es) Variantes de gpr156 y usos de estas
PH12019500596B1 (en) Recombinant binding proteins and their use
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12019500209A1 (en) Methods and compositions for gene expression in plants
MX2019004810A (es) Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
HRP20231707T1 (hr) Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47
MX2017008670A (es) Moleculas artificiales de acido nucleico novedosas.
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
SG10201808565QA (en) Fgfr fusions
RU2020122439A (ru) Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
HRP20240855T1 (hr) Neljudske životinje koje imaju humanizirani gen cd274 iz diferencijacijske skupine
HK1243958A1 (zh) 核酸构建体
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
JP2019500414A5 (https=)
CY1119976T1 (el) Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων
SG10201901053TA (en) Novel tilapia virus and uses thereof
BR112016017723A2 (pt) nucleotídeo de fitase de pteris vittata e sequências de aminoácido e métodos de uso
NZ724196A (en) Uti fusion proteins
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
NZ752941A (en) Frataxin expression constructs
MX2021002135A (es) Secuencia génica de gtpasa similar a dineína mitocondrial de tipo ii humana recombinante y usos de esta.
BR112018068890A2 (pt) dna polimerases marinhas
EP3795586A3 (en) Production of proteins in labyrinthulomycetes
PH12017501148A1 (en) Pesticidal genes and methods of use